Antibody-drug conjugates
Antibodies linked to chemotherapy, such as trastuzumab deruxtecan.
Key point
Recent positive phase III trial data have further incorporated ADCs into standard of care in several solid tumours, while predictive biomarker development remains essential.
From: Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation (ESMO Open, 2026 Aug) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 100, 118, 171, 230, 265.
New guidelines and consensus this year
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia, version 2.0J Immunother Cancer2026 Sep 21
- Knowledge, Awareness, and Practice Patterns of Nephrologists in the Diagnosis and Management of Multiple Myeloma (MIND-MM Study): A Cross-Sectional, Web-Based, CHERRIES-Compliant Survey with Position Statement from the Indian Myeloma Academic Groupe (IMAGe) and Indian Society of Nephrology (ISN)Clin Lymphoma Myeloma Leuk2026 Sep
- Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular TherapyTransplant Cell Ther2026 Aug 18
- Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners FoundationESMO Open2026 Aug
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and VenereologyClin Transl Oncol2026 Jul
All papers from the last 12 months
2,958 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Identification and quantitation strategies of circulating cysteine-conjugated linker-payload catabolites and free payload from a cleavable-linker ADCJ Pharm Biomed Anal2027 Jan 1PMID 42594803
- Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapyOncoimmunology2026 Dec 31PMID 42873150
- Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumorsDrug Deliv2026 Dec 31PMID 42557654
- Trial watch: antibody-drug conjugates in cancer therapyOncoimmunology2026 Dec 31PMID 42070121Review
- Targeting IL-7Rα with PNU-159682 antibody-drug conjugates in acute lymphoblastic leukemia: translational implicationsMAbs2026 Dec 31PMID 42046337
- Extracellular payload release from non-internalizing antibody-drug conjugates: mechanisms and linker technologiesDrug Deliv2026 Dec 31PMID 41866709Review
- Rapid and selective characterization of antibody-drug conjugates in complex sample matrices by native affinity liquid chromatography-mass spectrometryMAbs2026 Dec 31PMID 41548089
- The role of fibronectin in the tumor microenvironment - implications for immunotherapyCell Cycle2026 Dec 15PMID 42798197Review
- MetaVision-SPR: a 96-well chromatic Meta-SPR imaging platform for tumor biomarker quantification and apparent kinetic prescreeningBiosens Bioelectron2026 Dec 15PMID 42696820
- Potential small-molecule tyrosine kinase inhibitors (TKIs) for the treatment of triple-negative breast cancer (TNBC): Targets, structure-activity relationships, and clinical studiesEur J Med Chem2026 Dec 5PMID 42612290Review
More oncology trends
All specialties →Claudin 18.2
Claudin 18.2 as a target in gastric and oesophageal cancer.
Key point: Zolbetuximab is recommended for patients with gastroesophageal adenocarcinoma, PD-L1 <1, and positive CLDN18.2 expression.
Circulating tumour DNA
Liquid biopsy with ctDNA for detection, monitoring and treatment decisions.
Key point: ctDNA testing may be used when tissue testing is challenging, infeasible, risky, delayed, or required by drug indication; negative/inconclusive results should prompt tissue confirmation.
Perioperative immunotherapy
Immune checkpoint inhibitors given before and after cancer surgery.
Bispecific antibodies in solid tumours
Bispecific antibodies such as tarlatamab, amivantamab and ivonescimab.
Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"antibody-drug conjugate*"[tiab] OR "trastuzumab deruxtecan"[tiab] OR "sacituzumab govitecan"[tiab] OR "datopotamab deruxtecan"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.